News

OneSource strategic lab solutions will deliver PerkinElmer’s informatics, instrumentation, service and process optimization, to increase laboratories’ productivity and performance. Due to limited access to laboratory personnel, the information

The company along with the National Research Council Canada have identified the potential of sCLU in inducing EMT. EMT mechanism plays a key role in tumor invasion and

The LUX-Lung 6 trial has shown that patients with epidermal epidermal growth factor receptor (EGFR or ErbB1) mutation-positive advanced NSCLC treated first-line with afatinib lived for almost a

The contract is funded by the Defense Threat Reduction Agency (DTRA). According to the terms of the company’s contract with the Science and Technology Corporation, anti-ricin antibodies will

The first and only subcutaneously administered anti-tumor necrosis factor (TNF)-alpha therapy is approved to induce and maintain clinical response and improve endoscopic appearance of the mucosa during induction.

The therapy is indicated for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone. Xofigo was approved three months ahead of schedule under

Nuvo Europe and Immunology Group president Henrich Guntermann said that the company has been able to secure additional patent protection in the field of airway diseases for WF10

The tablets are used for the initial treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have certain epidermal growth factor receptor (EGFR) activating mutations

Panorama was launched in March 2013 for the detection of trisomy 21, trisomy 18, trisomy 13 and select sex chromosome abnormalities, such as monosomy X. Echevarne CEO Alfonso